SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Fred Saad, Kurt Miller, Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer, Urology, 2015,

    CrossRef

  2. 2
    Steven J Conrad, Mohamed El-Aswad, Esaw Kurban, David Jeng, Brian C Tripp, Charles Nutting, Robert Eversole, Charles Mackenzie, Karim Essani, Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice, Journal of Experimental & Clinical Cancer Research, 2015, 34, 1

    CrossRef

  3. 3
    Sanjay Srivatsan, Jaina M Patel, Erica N Bozeman, Imade E Imasuen, Sara He, Danielle Daniels, Periasamy Selvaraj, Allogeneic tumor cell vaccines, Human Vaccines & Immunotherapeutics, 2014, 10, 1, 52

    CrossRef

  4. 4
    Howard L Kaufman, Carl E Ruby, Tasha Hughes, Craig L Slingluff, Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma, Journal for ImmunoTherapy of Cancer, 2014, 2, 1, 11

    CrossRef

  5. 5
    Brian Wan-Chi Tse, Lidija Jovanovic, Colleen Coyne Nelson, Paul de Souza, Carl Andrew Power, Pamela Joan Russell, From Bench to Bedside: Immunotherapy for Prostate Cancer, BioMed Research International, 2014, 2014, 1

    CrossRef

  6. 6
    Harm Westdorp, Annette E. Sköld, Berit A. Snijer, Sebastian Franik, Sasja F. Mulder, Pierre P. Major, Ronan Foley, Winald R. Gerritsen, I. Jolanda M. de Vries, Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens, Frontiers in Immunology, 2014, 5,

    CrossRef

  7. 7
    Cristina Suárez, Rafael Morales-Barrera, Victor Ramos, Isaac Núñez, Claudia Valverde, Jacques Planas, Juan Morote, Xavier Maldonado, Joan Carles, Role of Immunotherapy in Castration-Resistant Prostate Cancer (CRPC), BJU International, 2014, 113, 3
  8. 8
    Jorge A. Garcia, Paul Elson, Allison Tyler, Pierre Triozzi, Robert Dreicer, Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): Results from a phase I-II clinical trial, Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1, 33.e11

    CrossRef

  9. 9
    Ignacio Melero, Gustav Gaudernack, Winald Gerritsen, Christoph Huber, Giorgio Parmiani, Suzy Scholl, Nicholas Thatcher, John Wagstaff, Christoph Zielinski, Ian Faulkner, Håkan Mellstedt, Therapeutic vaccines for cancer: an overview of clinical trials, Nature Reviews Clinical Oncology, 2014, 11, 9, 509

    CrossRef

  10. 10
    Naoki Hosen, Tetsuo Maeda, Yoshiko Hashii, Akihiro Tsuboi, Sumiyuki Nishida, Jun Nakata, Yoshiki Nakae, Satoshi Takashima, Yusuke Oji, Yoshihiro Oka, Atsushi Kumanogoh, Haruo Sugiyama, Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects, Expert Review of Hematology, 2014, 7, 5, 671

    CrossRef

  11. 11
    Patrick A. Ott, Edward F. Fritsch, Catherine J. Wu, Glenn Dranoff, Vaccines and Melanoma, Hematology/Oncology Clinics of North America, 2014, 28, 3, 559

    CrossRef

  12. 12
    Ute E. Burkhardt, Ursula Hainz, Kristen Stevenson, Natalie R. Goldstein, Mildred Pasek, Masayasu Naito, Di Wu, Vincent T. Ho, Anselmo Alonso, Naa Norkor Hammond, Jessica Wong, Quinlan L. Sievers, Ana Brusic, Sean M. McDonough, Wanyong Zeng, Ann Perrin, Jennifer R. Brown, Christine M. Canning, John Koreth, Corey Cutler, Philippe Armand, Donna Neuberg, Jeng-Shin Lee, Joseph H. Antin, Richard C. Mulligan, Tetsuro Sasada, Jerome Ritz, Robert J. Soiffer, Glenn Dranoff, Edwin P. Alyea, Catherine J. Wu, Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells, Journal of Clinical Investigation, 2013, 123, 9, 3756

    CrossRef

  13. 13
    Archana Thakur, Ulka Vaishampayan, Lawrence Lum, Immunotherapy and Immune Evasion in Prostate Cancer, Cancers, 2013, 5, 2, 569

    CrossRef

  14. 14
    L Qin, B D Smith, H-L Tsai, N K Yaghi, P H Neela, M Moake, J Fu, YL Kasamon, G T Prince, M Goswami, G L Rosner, H I Levitsky, C S Hourigan, Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy, Blood Cancer Journal, 2013, 3, 9, e145

    CrossRef

  15. 15
    Alexandra Drakaki, David F. McDermott, Novel Immunotherapies in GU Malignancies, Current Oncology Reports, 2013, 15, 3, 224

    CrossRef

  16. 16
    Alexandra Snyder, Jaron E. Tepper, Susan F. Slovin, Perspectives on Immunotherapy in Prostate Cancer and Solid Tumors: Where Is the Future?, Seminars in Oncology, 2013, 40, 3, 347

    CrossRef

  17. 17
    Stéphane Oudard, Progress in emerging therapies for advanced prostate cancer, Cancer Treatment Reviews, 2013, 39, 3, 275

    CrossRef

  18. 18
    Sean M. Geary, Caitlin D. Lemke, David M. Lubaroff, Aliasger K. Salem, Proposed mechanisms of action for prostate cancer vaccines, Nature Reviews Urology, 2013, 10, 3, 149

    CrossRef

  19. 19
    Sean M. Geary, Aliasger K. Salem, Prostate cancer vaccines, OncoImmunology, 2013, 2, 5, e24523

    CrossRef

  20. 20
    Satoshi Wada, Christopher M Jackson, Kiyoshi Yoshimura, Hung-Rong Yen, Derese Getnet, Timothy J Harris, Monica V Goldberg, Tullia C Bruno, Joseph F Grosso, Nicholas Durham, George J Netto, Drew M Pardoll, Charles G Drake, Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer, Journal of Translational Medicine, 2013, 11, 1, 89

    CrossRef

  21. 21
    Shuang Yin Zhang, Eddie Thara, David Quinn, Tanya Dorff, Blood cells and their use in active immunotherapy of prostate cancer, Human Vaccines & Immunotherapeutics, 2012, 8, 4, 528

    CrossRef

  22. 22
    Alfons JM van den Eertwegh, Jurjen Versluis, H Pieter van den Berg, Saskia JAM Santegoets, R Jeroen A van Moorselaar, Tim M van der Sluis, Helen E Gall, Thomas C Harding, Karin Jooss, Israel Lowy, Herbert M Pinedo, Rik J Scheper, Anita GM Stam, B Mary E von Blomberg, Tanja D de Gruijl, Kristen Hege, Natalie Sacks, Winald R Gerritsen, Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial, The Lancet Oncology, 2012, 13, 5, 509

    CrossRef

  23. 23
    Winald R. Gerritsen, Padmanee Sharma, Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy, Journal of Clinical Immunology, 2012, 32, 1, 25

    CrossRef

  24. 24
    Eddie Thara, Tanya B. Dorff, Monica Averia-Suboc, Michael Luther, Mary E. Reed, Jacek K. Pinski, David I. Quinn, Immune Response to Sipuleucel-T in Prostate Cancer, Cancers, 2012, 4, 4, 420

    CrossRef

  25. 25
    Guru Sonpavde, Philip W. Kantoff, Immunotherapy for Castration-Resistant Prostate Cancer, Urologic Clinics of North America, 2012, 39, 4, 465

    CrossRef

  26. You have free access to this content26
    John M. Kirkwood, Lisa H. Butterfield, Ahmad A. Tarhini, Hassane Zarour, Pawel Kalinski, Soldano Ferrone, Immunotherapy of cancer in 2012, CA: A Cancer Journal for Clinicians, 2012, 62, 5
  27. 27
    Noel W. Clarke, Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer, BJU International, 2012, 110,
  28. 28
    Daniel J. Lee, Eugene K. Cha, Justin M. Dubin, Himisha Beltran, Thomas F. Chromecki, Harun Fajkovic, Douglas S. Scherr, Scott T. Tagawa, Shahrokh F. Shariat, Novel therapeutics for the management of castration-resistant prostate cancer (CRPC), BJU International, 2012, 109, 7
  29. 29
    J. Bedke, C. Gouttefangeas, A. Stenzl, Prostatakarzinom, Der Urologe, 2012, 51, 1, 44

    CrossRef

  30. 30
    David M Lubaroff, Prostate cancer vaccines in clinical trials, Expert Review of Vaccines, 2012, 11, 7, 857

    CrossRef

  31. 31
    Nicolò Rigamonti, Matteo Bellone, Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy, Cancer Immunology, Immunotherapy, 2012, 61, 4, 453

    CrossRef

  32. 32
    G. Colloca, Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: A review, Cancer Treatment Reviews, 2012, 38, 8, 1020

    CrossRef

  33. 33
    Channing J. Paller, Emmanuel S. Antonarakis, Sipuleucel-T for the treatment of metastatic prostate cancer, Human Vaccines & Immunotherapeutics, 2012, 8, 4, 509

    CrossRef

  34. 34
    B. Molitor, C. Börgermann, Zweitlinientherapie beim kastrationsresistenten Prostatakarzinom (CRPC), Der Urologe, 2012, 51, 3, 357

    CrossRef

  35. 35
    Emmanuel S. Antonarakis, Michael A. Carducci, Mario A. Eisenberger, Campbell-Walsh Urology, 2012,

    CrossRef

  36. 36
    Aimee E. Hammerstrom, Diana H. Cauley, Bradley J. Atkinson, Padmanee Sharma, Cancer Immunotherapy: Sipuleucel-T and Beyond, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011, 31, 8
  37. 37
    Se Joong Kim, Sun Il Kim, Current Treatment Strategies for Castration-Resistant Prostate Cancer, Korean Journal of Urology, 2011, 52, 3, 157

    CrossRef

  38. 38
    Ravi A Madan, Jeanny B Aragon-Ching, James L Gulley, William L Dahut, From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer, Expert Review of Vaccines, 2011, 10, 6, 743

    CrossRef

  39. 39
    Giuseppe Di Lorenzo, Carlo Buonerba, Philip W. Kantoff, Immunotherapy for the treatment of prostate cancer, Nature Reviews Clinical Oncology, 2011, 8, 9, 551

    CrossRef

  40. 40
    Marijo Bilusic, Christopher Heery, Ravi A. Madan, Immunotherapy in prostate cancer: Emerging strategies against a formidable foe, Vaccine, 2011, 29, 38, 6485

    CrossRef

  41. 41
    Qiushan He, Jinlong Li, Weihua Yin, Zhichun Song, Zhen Zhang, Tienan Yi, Jia Tang, Demin Wu, Yue Lu, Zhen Wang, Dan Liu, Xiaoren Zhang, Zhiming Hu, Jimin Gao, Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer, Cancer Immunology, Immunotherapy, 2011, 60, 5, 715

    CrossRef

  42. 42
    Sarah E. Church, Shawn M. Jensen, Christopher G. Twitty, Keith Bahjat, Hong-Ming Hu, Walter J. Urba, Bernard A. Fox, Multiple Vaccinations, The Cancer Journal, 2011, 17, 5, 379

    CrossRef

  43. 43
    Himisha Beltran, Tomasz M. Beer, Michael A. Carducci, Johann de Bono, Martin Gleave, Maha Hussain, William K. Kelly, Fred Saad, Cora Sternberg, Scott T. Tagawa, Ian F. Tannock, New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety, European Urology, 2011, 60, 2, 279

    CrossRef

  44. 44
    T. Nelius, K. Rinard, S. Filleur, Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer – Review of the literature, Cancer Treatment Reviews, 2011, 37, 6, 444

    CrossRef

  45. 45
    Guru Sonpavde, Neeraj Agarwal, Toni K Choueiri, Philip W Kantoff, Recent advances in immunotherapy for the treatment of prostate cancer, Expert Opinion on Biological Therapy, 2011, 11, 8, 997

    CrossRef

  46. You have free access to this content46
    Sujitra Detchokul, Albert G. Frauman, Recent developments in prostate cancer biomarker research: therapeutic implications, British Journal of Clinical Pharmacology, 2011, 71, 2
  47. 47
    Yael S. Barach, Jun Sik Lee, Xingxing Zang, T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics, Trends in Molecular Medicine, 2011, 17, 1, 47

    CrossRef

  48. 48
    Minh C. Nguyen, Guang Huan Tu, Kathryn E. Koprivnikar, Melissa Gonzalez-Edick, Karin U. Jooss, Thomas C. Harding, Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy, Cancer Immunology, Immunotherapy, 2010, 59, 9, 1313

    CrossRef

  49. 49
    Dirk Schrijvers, Peter Van Erps, Jim Cortvriend, Castration-refractory prostate cancer: New drugs in the pipeline, Advances in Therapy, 2010, 27, 5, 285

    CrossRef

  50. 50
    Dung T. Le, Drew M. Pardoll, Elizabeth M. Jaffee, Cellular Vaccine Approaches, The Cancer Journal, 2010, 16, 4, 304

    CrossRef

  51. 51
    Emmanuel S Antonarakis, Charles G Drake, Current status of immunological therapies for prostate cancer, Current Opinion in Urology, 2010, 20, 3, 241

    CrossRef

  52. 52
    Rachel Lubong Sabado, Nina Bhardwaj, Directing dendritic cell immunotherapy towards successful cancer treatment, Immunotherapy, 2010, 2, 1, 37

    CrossRef

  53. 53
    D. Bianchini, A. Zivi, S. Sandhu, J. S. de Bono, Horizon scanning for novel therapeutics for the treatment of prostate cancer, Annals of Oncology, 2010, 21, Supplement 7, vii43

    CrossRef

  54. 54
    Kanako Shimizu, Michihiro Hidaka, Kara Bickham, Mina Moriwaki, Koji Fujimoto, Fumio Kawano, Shin-ichiro Fujii, Human leukemic cells loaded with α-galactosylceramide (α-GalCer) activate murine NKT cells in situ, International Journal of Hematology, 2010, 92, 1, 152

    CrossRef

  55. You have full text access to this Open Access content55
    Hirotsugu Uemura, Kiyohide Fujimoto, Takashi Mine, Shigeya Uejima, Marco A. De Velasco, Yoshihiko Hirao, Nobukazu Komatsu, Akira Yamada, Kyogo Itoh, Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer, Cancer Science, 2010, 101, 3
  56. 56
    Charles G. Drake, Immunotherapy for Prostate Cancer: An Emerging Treatment Modality, Urologic Clinics of North America, 2010, 37, 1, 121

    CrossRef

  57. 57
    Emmanuel S. Antonarakis, Michael A. Carducci, Mario A. Eisenberger, Novel targeted therapeutics for metastatic castration-resistant prostate cancer, Cancer Letters, 2010, 291, 1, 1

    CrossRef

  58. 58
    Charles G. Drake, Prostate cancer as a model for tumour immunotherapy, Nature Reviews Immunology, 2010, 10, 8, 580

    CrossRef

  59. 59
    Diletta Bianchini, Andrea Zivi, Shahneen Sandhu, Johann S de Bono, RETRACTED: Horizon scanning for novel therapeutics for the treatment of prostate cancer, Expert Opinion on Investigational Drugs, 2010, 19, 12, 1487

    CrossRef

  60. 60
    Matteo Vergati, Chiara Intrivici, Ngar-Yee Huen, Jeffrey Schlom, Kwong Y. Tsang, Strategies for Cancer Vaccine Development, Journal of Biomedicine and Biotechnology, 2010, 2010, 1

    CrossRef

  61. 61
    Flora Stavridi, Eleni M. Karapanagiotou, Kostas N. Syrigos, Targeted therapeutic approaches for hormone-refractory prostate cancer, Cancer Treatment Reviews, 2010, 36, 2, 122

    CrossRef

  62. You have free access to this content62
    Guru Sonpavde, Cora N Sternberg, The role of docetaxel based therapy for prostate cancer in the era of targeted medicine, International Journal of Urology, 2010, 17, 3
  63. 63
    Taylor H. Schreiber, Luis Raez, Joseph D. Rosenblatt, Eckhard R. Podack, Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art, Seminars in Immunology, 2010, 22, 3, 105

    CrossRef

  64. 64
    Charles G. Drake, Emmanuel S. Antonarakis, Update: Immunological Strategies for Prostate Cancer, Current Urology Reports, 2010, 11, 3, 202

    CrossRef

  65. 65
    Britta Randlev, Li-chun Huang, Mitsuko Watatsu, Matthew Marcus, Andy Lin, Shian-Jiun Shih, Validation of a quantitative flow cytometer assay for monitoring HER-2/neu expression level in cell-based cancer immunotherapy products, Biologicals, 2010, 38, 2, 249

    CrossRef

  66. 66
    Li-Chun Huang, Wendy Lin, Machiko Yagami, Daphne Tseng, Emily Miyashita-Lin, Nitasha Singh, Andy Lin, Shian-Jiun Shih, Validation of cell density and viability assays using Cedex automated cell counter, Biologicals, 2010, 38, 3, 393

    CrossRef

  67. 67
    Jun Hyuk Hong, What's New in Hormone-refractory Prostate Cancer Treatment, Journal of the Korean Medical Association, 2010, 53, 2, 126

    CrossRef

  68. 68
    Betty Li, Andrew Simmons, Thomas Du, Carol Lin, Marina Moskalenko, Melissa Gonzalez-Edick, Melinda VanRoey, Karin Jooss, Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies, Clinical Immunology, 2009, 133, 2, 184

    CrossRef

  69. 69
    Kim N. Chi, Anders Bjartell, David Dearnaley, Fred Saad, Fritz H. Schröder, Cora Sternberg, Bertrand Tombal, Tapio Visakorpi, Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets, European Urology, 2009, 56, 4, 594

    CrossRef

  70. 70
    Shin-ichiro Fujii, Takuya Takayama, Miki Asakura, Kaori Aki, Koji Fujimoto, Kanako Shimizu, Dendritic cell-based cancer immunotherapies, Archivum Immunologiae et Therapiae Experimentalis, 2009, 57, 3, 189

    CrossRef

  71. 71
    Kiran Lassi, Nancy A Dawson, Emerging therapies in castrate-resistant prostate cancer, Current Opinion in Oncology, 2009, 21, 3, 260

    CrossRef

  72. 72
    M.A. Reiter, J. Pfitzenmaier, M. Hohenfellner, A. Haferkamp, Immunmodulatorische Therapieansätze beim Prostatakarzinom, Der Urologe, 2009, 48, 7, 755

    CrossRef

  73. 73
    Takayuki Yoshimoto, Noriko Morishima, Masae Okumura, Yukino Chiba, Mingli Xu, Junichiro Mizuguchi, Interleukins and cancer immunotherapy, Immunotherapy, 2009, 1, 5, 825

    CrossRef

  74. 74
    Susan Feyerabend, Stefan Stevanovic, Cécile Gouttefangeas, Dorothee Wernet, Jörg Hennenlotter, Jens Bedke, Klaus Dietz, Steve Pascolo, Markus Kuczyk, Hans-Georg Rammensee, Arnulf Stenzl, Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer, The Prostate, 2009, 69, 9
  75. 75
    Thomas H. Brill, Hubert R. Kübler, Heike Pohla, Alexander Buchner, Falko Fend, Tibor Schuster, Heiner van Randenborgh, Roger Paul, Tania Kummer, Christian Plank, Bernd Eisele, Jürgen Breul, Rudolf Hartung, Dolores J. Schendel, Bernd Gansbacher, Therapeutic Vaccination with an Interleukin-2–Interferon-γ-Secreting Allogeneic Tumor Vaccine in Patients with Progressive Castration-Resistant Prostate Cancer: A Phase I/II Trial, Human Gene Therapy, 2009, 20, 12, 1641

    CrossRef